Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment
Unknown status
Glaxo Wellcome
Phase 4
1969-12-31
The purpose of this study is to see how effective and safe it is to give 1 of the 3 following
treatments to patients who may not have received anti-HIV treatment: 1) lamivudine
(3TC)/abacavir (ABC)/stavudine (d4T); 2) 3TC/ABC/efavirenz (EFV); or 3) 3TC/ABC/amprenavir
(APV)/ritonavir (RTV).
Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults
Completed
AIDS Clinical Trials Group
N/A
2003-10-01
HIV replication in resting CD4 cells is so minimal that anti-HIV drugs often fail to destroy
the virus in these cells. Enfuvirtide, also known as T-20, is a type of anti-HIV drug called
a fusion inhibitor. The purpose of this study is to test the ability of a T-20-enhanced
treatment regimen to decrease the number of resting CD4 cells that become infected with HIV.
Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
N/A
2003-10-01
HIV replication in resting CD4 cells is so minimal that anti-HIV drugs often fail to destroy
the virus in these cells. Enfuvirtide, also known as T-20, is a type of anti-HIV drug called
a fusion inhibitor. The purpose of this study is to test the ability of a T-20-enhanced
treatment regimen to decrease the number of resting CD4 cells that become infected with HIV.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
